ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 628,57
-0,56%
Dow Jones
39 150,33
0,04%
DAX
18 163,52
-0,41%
Brent Oil
84,39
0,00%
Bitcoin
64 066,99
-0,28%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Zymeworks Inc (ZYME)

  7. Zymeworks Inc (ZYME) Actualités

ZYME

Zymeworks (ZYME)

Zymeworks Inc
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:ZYME
DateHeureSourceTitreSymboleSociété
29/06/202322h12Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
21/06/202322h05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
12/06/202322h26Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NYSE:ZYMEZymeworks Inc
03/06/202301h23PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract CancersNYSE:ZYMEZymeworks Inc
08/05/202323h20Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:ZYMEZymeworks Inc
28/04/202322h18Edgar (US Regulatory)Amended Annual Report (10-k/a)NYSE:ZYMEZymeworks Inc
07/03/202323h25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NYSE:ZYMEZymeworks Inc
14/02/202322h47Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
25/01/202314h30Business WireZymeworks Announces Participation in Upcoming Investor ConferencesNYSE:ZYMEZymeworks Inc
19/01/202313h45PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaNYSE:ZYMEZymeworks Inc
04/01/202322h15Business WireZymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023NYSE:ZYMEZymeworks Inc
03/01/202323h02Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:ZYMEZymeworks Inc
28/12/202222h36Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NYSE:ZYMEZymeworks Inc
21/12/202213h30Business WireZymeworks Announces Participation in Upcoming Investor ConferenceNYSE:ZYMEZymeworks Inc
19/12/202213h00Business WireZymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of ZanidatamabNYSE:ZYMEZymeworks Inc
14/12/202222h15Business WireZanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers SymposiumNYSE:ZYMEZymeworks Inc
09/12/202214h00Business WireNew Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCSNYSE:ZYMEZymeworks Inc
05/12/202214h30Business WireZymeworks to Transfer Stock Listing to NasdaqNYSE:ZYMEZymeworks Inc
29/11/202214h30Business WireZymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz PharmaceuticalsNYSE:ZYMEZymeworks Inc
23/11/202204h41TipRanksAnalysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Enanta Pharmaceuticals (ENTA) and Zymeworks (ZYME)NYSE:ZYMEZymeworks Inc
21/11/202215h00Business WireZymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)NYSE:ZYMEZymeworks Inc
10/11/202205h35TipRanksSVB Securities Remains a Hold on Zymeworks (ZYME)NYSE:ZYMEZymeworks Inc
08/11/202222h22Business WireZymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsNYSE:ZYMEZymeworks Inc
01/11/202214h35TipRanksZymeworks (ZYME) was downgraded to a Hold Rating at H.C. WainwrightNYSE:ZYMEZymeworks Inc
24/10/202218h31TipRanksAnalysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Zymeworks (ZYME)NYSE:ZYMEZymeworks Inc
20/10/202214h30Business WireZymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology PlatformsNYSE:ZYMEZymeworks Inc
19/10/202213h31TipRanksZymeworks Rises on Jazz Pharma DealNYSE:ZYMEZymeworks Inc
19/10/202212h07Business WireZymeworks To Host Conference Call on Exclusive Licensing Agreement of ZanidatamabNYSE:ZYMEZymeworks Inc
19/10/202212h00PR Newswire (Canada)Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific AntibodyNYSE:ZYMEZymeworks Inc
18/10/202214h30Business WireZymeworks to Host Third Quarter Results Conference CallNYSE:ZYMEZymeworks Inc
 Showing the most relevant articles for your search:NYSE:ZYME

Dernières Valeurs Consultées

EU
CFFCG
Compagnie de Financement...
ASX
ATG
Articore
TG
A1871T
UniCredit
BOV
ITUBF346
ITUBF346 Ex:33,23
BIT
P1T7P3
NLBNPIT1T7P3 20240621 2300
EU
EZN1N
Euronext Eurozone Next 1...
TSXV
ASD
BSTP
YFIBTC
yearn.finance
EU
I3AMD
LS 3AMD INAV
BIT
1SPG
Simon Property
LSE
81GI
Rbts Ned Bv 30s
USOTC
ASCHF
Acotec Scientific (PK)
TG
A2RSLQ
BNP Paribas Fortis
COIN
TXAUST
TXA
LSE
AO92
Res Mtg 12 C A
TG
PPXC
Kering
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés